Sutro Biopharma (STRO) Research & Development (2017 - 2025)

Sutro Biopharma has disclosed Research & Development across 9 years of filings, most recently posting $36.6 million for Q4 2025.

• Research & Development for Q4 2025 came in at $36.6 million, down 48.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $166.4 million (down 33.97% YoY), and the FY2025 annual result was $166.4 million, down 33.97% from the prior year.
• Research & Development came in at $36.6 million for Q4 2025 at Sutro Biopharma, down from $39.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $71.0 million in Q4 2024 to a low of $22.6 million in Q1 2021.
• The 5-year median for Research & Development is $39.6 million (2023), against an average of $42.0 million.
• Across the five-year window, Research & Development soared 49.12% in 2024 and tumbled 48.42% in 2025, its largest moves.
• Sutro Biopharma's Research & Development stood at $29.9 million in 2021, then soared by 44.13% to $43.1 million in 2022, then grew by 24.64% to $53.8 million in 2023, then jumped by 32.12% to $71.0 million in 2024, then sank by 48.42% to $36.6 million in 2025.
• The last three Research & Development figures came in at $36.6 million (Q4 2025), $39.9 million (Q3 2025), and $38.3 million (Q2 2025), per Business Quant data.